Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vivos Therapeutics Inc (NQ: VVOS ) 2.610 -0.090 (-3.33%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Vivos Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 10 Next > Crude Oil Gains Over 1%; Mobileye Global Shares Jump September 19, 2024 Via Benzinga Exposures Fossil Fuels Dow Jumps Over 500 Points; FactSet Research Posts Upbeat Earnings September 19, 2024 Via Benzinga Topics Stocks Exposures US Equities Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today September 19, 2024 Vivos Therapeutics shares are trading lower by 25% Thursday morning. The company announced a $4.3 million registered offering. Via Benzinga TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces $4.3M Registered Direct Offering September 19, 2024 Via Investor Brand Network Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000 September 19, 2024 Via Benzinga Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today September 18, 2024 NVDA, TMUS, VVOS, SOFI, TSLA are the top trending stocks on Wednesday. Via Benzinga Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children September 18, 2024 The FDA has granted 510(k) clearance to Vivos Therapeutics' DNA oral appliance for treating moderate to severe obstructive sleep apnea and snoring in children aged 6-17. Via Benzinga Exposures Product Safety InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Awarded First-Ever FDA Clearance for Pediatric Treatment of Sleep Apnea, Snoring September 18, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Report on Q2 2024 Financial Results, Operational Update August 15, 2024 Via Investor Brand Network VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 14, 2024 VVOS stock results show that Vivos Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Plans Release of Q2 2024 Financial Results, Conference Call August 14, 2024 Via Investor Brand Network TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Reports Results of Seven-Month Provider-Based Marketing and Distribution Model Pilot June 27, 2024 Via Investor Brand Network InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Announces Strategic Alliance, Private Equity Investment June 12, 2024 Via Investor Brand Network Exposures Product Safety InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Releases Q1 2024 Financial Report, Operational Update May 15, 2024 Via Investor Brand Network 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 15, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday May 15, 2024 We are covering the biggest pre-market stock movers for Wednesday with all of the latest happenings worth watching this morning! Via InvestorPlace VVOS Stock Earnings: Vivos Therapeutics Reported Results for Q1 2024 May 14, 2024 Vivos Therapeutics just reported results for the first quarter of 2024. Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's After-Market Session May 14, 2024 Via Benzinga InvestorNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Schedules Release of Q1 2024 Results, Conference Call May 14, 2024 Via Investor Brand Network TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) CEO Discusses Medicare Reimbursement Approval for CARE Oral Medical Devices in Proactive Interview April 10, 2024 Via Investor Brand Network Topics Product Recall Exposures Legal Product Safety TinyGemsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Achieves Milestone with CARE Oral Medical Devices Gaining Approval for Medicare Reimbursement April 09, 2024 Via Investor Brand Network What's Going On With Vivos Therapeutics Stock? April 09, 2024 Vivos Therapeutics shares are trading lower Tuesday. The company filed a prospectus related to the resale of up to 1.73 million shares of common stock by selling shareholders. Vivos said that if the... Via Benzinga Why Is Laser Photonics (LASE) Stock Up 130% Today? April 09, 2024 Laser Photonics stock is rising higher on Tuesday as LASE investors celebrate a new unit order from L3Harris Technologies. Via InvestorPlace Why Is Vivos Therapeutics (VVOS) Stock Up 16% Today? April 09, 2024 Vivos Therapeutics stock is up on Tuesday as VVOS investors react to the company securing full Medicare reimbursement for its OSA device. Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday April 09, 2024 Pre-market stock movers are worth checking out as we get into all of the hottest news investors need to know about on Tuesday morning! Via InvestorPlace Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket April 01, 2024 Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session April 01, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday April 01, 2024 It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning! Via InvestorPlace 12 Health Care Stocks Moving In Friday's After-Market Session March 29, 2024 Via Benzinga VVOS Stock Earnings: Vivos Therapeutics Misses EPS, Misses Revenue for Q4 2023 March 28, 2024 VVOS stock results show that Vivos Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.